MedWorm: Non-Hodgkin’s Lymphoma
|
|
|
|
MedWorm.com provides a medical RSS filtering service. Over 5500 RSS medical sources are combined and output via different filters. This feed contains the latest headlines from journals and sites in the Non-Hodgkin’s Lymphoma category.
MedWorm: Non-Hodgkin's Lymphoma
MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest headlines from journals and sites in the Non-Hodgkin's Lymphoma category.
Primary hepatic lymphoma presenting as fulminant hepatic failure with hyperferritinemia: a case report
IntroductionPrimary hepatic lymphoma is an unusual form of non-Hodgkin's lymphoma that usually presents with constitutional symptoms, hepatomegaly and signs of cholestatic jaundice. Diffuse hepatic infiltration is uncommon and presentation with acute hepatic failure even more rare. The presence of markedly elevated ferritin levels can complicate the evaluation process and suggest alternative diagnoses.
Case Presentation
We present the case of a middle-aged woman exhibiting pancytopenia, hyperferritinemia and rapidly deteriorating to develop acute hepatic failure. Her initial clinical picture led to a working diagnosis of adult onset Still's disease with probable hemophagocytic syndrome before her worsening liver function necessitated a percutaneous liver biopsy and establishment of the final diagnosis of primary hepatic lymphoma.
Conclusions:
Primary hepatic lymphoma is an uncommon malignancy and its manifestation as progressive hepatitis or acute fulminant hepatic failure can be difficult to diagnose. The presence of constitutional symptoms, pancytopenia and high ferritin levels can complicate the evaluation process. A liver biopsy early in the course of liver dysfunction may establish the diagnosis without a higher risk of bleeding complications seen once liver failure sets in. (Source: BioMed Central)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease
Palladino M, Miele L, Pompili M, Forgione A, Vellone V, Vecchio FM, Chiusolo P, Laurenti L, Gasbarrini G, Sica S, Grieco A. Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease.Clin Transplant 2008 DOI: 10.1111/j.1399-0012.2008.00882.x © 2008 Wiley Periodicals, Inc.Abstract: Veno-occlusive disease (VOD) of the liver is a severe complication of high-dose chemotherapy and allogeneic or autologous stem cell transplantation with potential fatal outcome. We report a case of severe VOD in a patient with a high-grade B-cell lymphoma. Liver-venule occlusion was confirmed by liver biopsy. Supportive care, fibrinolytic treatment with recombinant tissue plasminogen activator and defibrotide maintenance therapy led to complete resolution of VOD demonstrated at liver biopsy and with a follow-up of 44 months after autologous peripheral blood stem cell transplantation. The literature on VOD has been reviewed. (Source: Clinical Transplantation)
Expression of a soluble decoy receptor 3 in patients with diffuse large b-cell lymphoma predicts clinical outcome.
Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Int J Oncol. 2008 Sep;33(3):549-54
Authors: Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH
The soluble decoy receptor 3 (DcR3) is a member of the TNF receptor superfamily. It is regarded as a decoy receptor released from tumor cells to escape host immune response by neutralizing the cytotoxic and immunomodulatory effects of FasL, LIGHT and TL1A. Overexpression of DcR3 has been observed in several human malignancies; however, only limited information exists on the role of DcR3 in non-Hodgkin lymphoma especially for B-cell origin. In the current study, the expression profile of DcR3 was analyzed by RT-PCR and immunohistochemistry (IHC) in a set of lymphoma cell lines including T-cell and B-cell lymphomas. The result demonstrated that overexpression of DcR3 was detected in most T-cell lymphoma cells, which was consistent with previous reports. Interestingly, overexpression of DcR3 was also detected both in the B-cell lymphoma cell lines and diffuse large B cell lymphoma (DLBCL) patients. DcR3 overexpression was associated with a worse prognosis in DLBCL patients (p=0.05). An in vitro study showed that neutralization of DcR3 increased the percentage of doxorubicin-mediated apoptosis in two B-cell lymphoma cell lines, which indicated the possibility of DcR3 mediated chemo-resistance in B-cell lymphomas. We suggest that overexpression of DcR3 is associated with a worse prognosis in DLBCL and the possible mechanism may act through the increase of chemo-resistance of lymphoma cells.
PMID: 18695885 [PubMed - in process]
(Source: International Journal of Oncology)Lenalidomide demonstrates activity in relapsed/refractory aggressive non-hodgkins lymphoma
Nonrandomized trial of lenalidomide in patients with relapsed/refractory NHL shows efficacy and acceptable toxicity profile (Source: Clinical Care Options Oncology - Lymphoma)
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Curr Pharm Des. 2008;14(21):2051-60
Authors: Bernard MP, Bancos S, Sime PJ, Phipps RP
There is much interest in the potential use of Cox-2 selective inhibitors in combination with other cancer therapeutics. Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase-2 (Cox-2), a key modulator of inflammation. For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis. Expression of Cox-2 enhances survival and proliferation of malignant cells, while negatively influencing anti-tumor immunity. Hematological malignancies expressing elevated levels of Cox-2 potentially avoid immune responses by producing factors that enhance angiogenesis and metastasis. Cellular immune responses regulated by natural killer cells, cytotoxic T lymphocytes, and T regulatory cells are also influenced by Cox-2 expression. Therefore, Cox-2 selective inhibitors have promising therapeutic potential in patients suffering from certain hematological malignancies.
PMID: 18691115 [PubMed - in process]
(Source: Current Pharmaceutical Design)Clinical relevance of cd10, bcl-6 and multiple myeloma-1 expression in diffuse large b-cell lymphomas in malaysia
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and it is recognized to constitute a heterogenous group of neoplasms. It can be divided into germinal center B-cell-like (GCB) and non-GCB subgroups. The aim of the present study was to evaluate the utility of immunophenotype subgrouping of DLBCL in a cohort of multi-ethnic Asian patients. A total of 84 reconfirmed de novo DLBCL were immunostained for the expression of CD10, BCL-2, BCL-6 and multiple myeloma-1. Thirty-three (39.3%) had the GCB phenotype, and the remainder (60.7%), the non-GCB phenotype. The results concur with most reports using a similar method of stratification. Forty-five patients had complete demographic and phenotype studies and 42 patients did not have rituximab treatment and had sufficient data for survival rate analysis. Similar to other studies, patients with combined low and low[ndash]intermediate International Prognostic Index score had better overall survival (P = 0.006). But patients with GCB phenotype did not have better prognosis, and BCL-2 expression was not associated with better prognosis. The expression of BCL-6 was associated with lower overall survival rate (P = 0.038). No apparent difference in overall and disease-free survival was noted between patients with GCB and non-GCB disease. BCL-6 expression by tumor cells appears to be associated with poorer prognosis. (Source: Pathology International)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Extended follow-up of the finnish cartilage-hair hypoplasia cohort confirms high incidence of non-hodgkin lymphoma and basal cell carcinoma
Cartilage-hair hypoplasia (CHH) is an autosomal recessive chondrodysplasia with short stature, sparse hair and defective cell-mediated immunity. It is caused by mutations in the RMRP (ribonuclease mitochondrial RNA processing) gene, encoding the RNA component of the ribonuclease complex RNase MRP. The aim of this study was to further elucidate the risk and spectrum of cancer in CHH. A cohort of 123 Finnish patients with CHH (51 males) was followed for malignancy through the Finnish Cancer Registry. The number of identified cancers was compared with expected numbers of cancer using population-based data to obtain standardized incidence ratios (SIR). Hospital records were reviewed for clinical data related to the malignancies. During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12). Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180) followed by squamous cell carcinoma (3), leukemia (1) and Hodgkin lymphoma (1). One tumor was not histologically classified. Nine of the 14 cancers were diagnosed in patients less than 45 years of age. In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61). Patients with CHH have significantly increased risk for developing non-Hodgkin lymphoma or basal cell carcinoma at early age; the overall prognosis is poor. The underlying pathogenetic mechanisms remain to be elucidated in future studies. Careful follow-up, extending beyond pediatric age, is warranted for early diagnosis of malignancies. © 2008 Wiley-Liss, Inc. (Source: American Journal of Medical Genetics Part A)
Second malignancies after treatment of diffuse large b-cell non-hodgkin's lymphoma: a gisl cohort study.
| Related Articles |
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.
Haematologica. 2008 Aug 12;
Authors: Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi PG, Angrilli F, Brugiatelli M, Musto P, Federico M
Background Improved treatment has increased the life expectancy of patients with non-Hodgkin's lymphoma, but few studies have addressed the issue of second cancer in patients treated for diffuse large B-cell lymphoma. The aims of this study were to determine the incidence and time free of second cancers in this subset of patients. DESIGN AND METHODS: We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treated between 1988 and 2003. We utilized the central database of the Gruppo Italiano Studio Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters, treatment and follow-up of all patients with non-Hodgkin's lymphoma enrolled in clinical trials. RESULTS: After a median follow-up of 51 months, 48 patients had developed a second cancer: 13 hematologic malignancies and 35 solid tumors. The overall standardized incidence ratio in our cohort (with a median age of 58 years) matched that of the general Italian population. The incidence ratio of second tumors was age related, and the age groups 20-39 and 40-59 years showed an increased risk. Overall, the cumulative incidence of second cancer was 8.2% at 15 years. A multivariate analysis showed that older age at the time of diagnosis of lymphoma had a negative influence on the time free of second tumors. Conclusions In our cohort, only young patients showed an increased incidence ratio of second malignancies, while the incidence ratio in patients aged over 59 years matched the incidence in the Italian general population. Demographics, baseline characteristics, laboratory parameters and treatment modalities did not have any significant impact on the incidence ratio of a second cancer.
PMID: 18698083 [PubMed - as supplied by publisher]
(Source: Haematologica)Night-time work predisposes to non-hodgkin lymphoma
Our aim was to find out whether non-Hodgkin lymphoma (NHL) was more common than expected among night-time shift workers. The Finnish job-exposure matrix (FINJEM) provided estimates of the proportion of exposed persons and the mean level of exposure among the exposed in each occupation. The probability of night-time work in each occupation was assessed, the observed and expected numbers of cancer cases in a cohort of persons born in 1906-1945 during the years of 1971-1995 were calculated, and the cumulative index of night-time work was scored. The cohort compromised of 1,669,272 persons of whom 6,307 (3,813 men and 2,494 women) had NHL during the follow-up. Night-time work increased significantly (p = 0.01) the risk of NHL in men, the overall relative risk being 1.10 (95% confidence interval of 1.03-1.19). Using the lag period of 10 years, the risk ratio was 1.28 (1.03-1.59) for men who worked in night-time shifts to a high degree as compared with those who had not been exposed to night-time work. Night-time workers are cancer prone and have a greater risk of NHL than population on average. © 2008 Wiley-Liss, Inc. (Source: International Journal of Cancer)
Cytological and immunological study of 139 patients with acute leukemia
Abstract Sixty-six children with acute lymphatic leukemia (ALL), 26 adults with ALL and 47 adults with acute myeloid leukemia (AML) were subclassified according to the classifications French-American-British (FAB) and World-Health-Organization (WHO). Nine immunological markers and 6 cytochemical stains were also used. The reproducibility of the WHO classification of the smears performed independently twice by one observer was 93%, but that between two observers only 78%. Three patients considered ALL by A were called AML by B, but all three had the common acute leukemia antigen, CALLA. In the group of 87 patients considered ALL by B, only 74 were classified ALL by A, but of the 13 non-ALL B, none had the CALLA. Ten of these thirteen patients had myeloid markers such as Philadelphia chromosomes, peroxidase of Sudan Black B positive reactions, or Fc and C3 receptors. The remaining 3 patients were non-Hodgkin lymphoma with B-cell markers. None of the 47 cases classified as AML had CALLA. Seventeen of nineteen myeloblastic leukemias (M2, FAB) had a myeloid antigen (Mag) and 13 of 15 myelomonocytic leukemias (M4, FAB) had, in addition, Fc and C3 receptors. Content Type Journal ArticleDOI 10.1007/BF02935318Authors J. Minowada, Roswell Park Memorial Institute Buffalo N.Y. USAG. Mathé, Hopital Paul-Brousse Institut de Cancérologie et d’Immunogénétique (I.N.S.E.R.M. U-50) 94804 Villejuif Cédex FranceM. Barcos, Roswell Park Memorial Institute Buffalo N.Y. USAM. Ginsbourg, Hopital Paul-Brousse Institut de Cancérologie et d’Immunogénétique (I.N.S.E.R.M. U-50) 94804 Villejuif Cédex FranceH. Preisler, Roswell Park Memorial Institute Buffalo N.Y. USAC. Canon, Hopital Paul-Brousse Institut de Cancérologie et d’Immunogénétique (I.N.S.E.R.M. U-50) 94804 Villejuif Cédex FranceP. Reizenstein, Hopital Paul-Brousse Institut de Cancérologie et d’Immunogénétique (I.N.S.E.R.M. U-50) 94804 Villejuif Cédex France Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 Journal Volume Volume 1 Journal Issue Volume 1, Number 1 / March, 1984 (Source: Medical Oncology)
Innexus marks milestone in development of non-hodgkin's lymphoma drug
InNexus Biotechnology Inc. is working with Covance Inc. testing a drug on monkeys for the prospective treatment of non-Hodgkin's lymphoma. (Source: bizjournals.com Health Care:Biotechnology headlines)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Innexus marks milestone in development of non-hodgkin's lymphoma drug
InNexus Biotechnology Inc. is working with Covance Inc. testing a drug on monkeys for the prospective treatment of non-Hodgkin's lymphoma. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Occupational exposures and non-hodgkin's lymphoma: canadian case-control study
Background: The objective was to study the association between Non-Hodgkin's Lymphoma (NHL) and occupational exposures related to long held occupations among males in six provinces of Canada. Methods: A population based case-control study was conducted from 1991 to 1994. Males with newly diagnosed NHL (ICD-10) were stratified by province of residence and age group. A total of 513 incident cases and 1506 population based controls were included in the analysis. Conditional logistic regression was conducted to fit statistical models. Results: Based on conditional logistic regression modeling, the following factors independently increased the risk of NHL: farmer and machinist as long held occupations; constant exposure to diesel exhaust fumes; constant exposure to ionizing radiation (radium); and personal history of another cancer. Men who had worked for 20 years or more as farmer and machinist were the most likely to develop NHL. Conclusions: An increased risk of developing NHL is associated with the following: long held occupations of farmer and machinist; exposure to diesel fumes; and exposure to ionizing radiation (radium). The risk of NHL increased with the duration of employment as a farmer or machinist. (Source: Environmental Health)
Incidence and mortality from non-hodgkin lymphoma in europe: the end of an epidemic?
Non-Hodgkin lymphomas (NHL) are among the few neoplasms whose incidence and mortality have been rising in Europe and North America over the last few decades. To update trends from NHL, we considered mortality data up to 2004 in several European countries, and for comparative purpose in the USA and Japan. We also analyzed patterns in incidence for selected European countries providing national data. In most European countries, NHL mortality rose up to the mid 1990s, and started to level off or decline in the following decade. The rates were, however, still increasing in eastern Europe. Overall, in the European Union, mortality from NHL declined from 4.3/100,000 to 4.1 in men and from 2.7 to 2.5 in women between the late 1990s and the early 2000s. Similarly, NHL mortality rates declined from 6.5/100,000 to 5.5 in US men and from 4.2 to 3.5 in US women. In most countries considered, NHL incidence rates rose up to 1995-99, while they tended to level off or decline thereafter, with particular favorable patterns in countries from northern Europe. Thus, the epidemic of NHL observed during the second half of the 20th century has now started to level off in Europe as in other developed areas of the world. © 2008 Wiley-Liss, Inc. (Source: International Journal of Cancer)
To protect and defend: central nervous system prophylaxis in patients with non-hodgkin's lymphoma.
Page: 495DOI: 10.1097/CCO.0b013e32830b829eAuthors: Lim, Hwee Yong a; Thiel, Eckhard b; Glantz, Michael J c (Source: Current Opinion in Oncology)
Follicular non-hodgkin lymphoma: long-term results of stem-cell transplantation.
Page: 502DOI: 10.1097/CCO.0b013e32830b61acAuthors: Barr, Paul M; Lazarus, Hillard M (Source: Current Opinion in Oncology)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Tricyclic-antidepressants linked to non-hodgkin's lymphoma
(Source: Inpharma)
Review article: drug therapy: monoclonal antibody therapy for b-cell non-hodgkin's lymphoma
Treatment of B-cell non-Hodgkin's lymphoma has become more successful, largely owing to the availability of therapeutic monoclonal antibodies, which may avoid the toxic effects of chemotherapy, improve the outcomes when combined with chemotherapy, and provide options for patients with refractory disease. This article reviews the current uses of monoclonal antibodies in B-cell non-Hodgkin's lymphoma. (Source: New England Journal of Medicine)
Cme: monoclonal antibody therapy for b-cell non-hodgkin's lymphoma
(No abstract is available for this citation) (Source: New England Journal of Medicine)
Fudan-cinpathogen study shows chronic lymphoid neoplasms are more common in shanghai than thought
A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China published online in the International Journal of Hematology shows significant differences in frequency of subtypes of lymphoma and other lymphoid neoplasms between China and the West. (Source: Lymphoma / Leukemia News From Medical News Today)
Fatal chylous ascites, pericarditis and extensive venous thrombosis, due to an aggressive t cell non-hodgkin lymphoma
Fatal chylous ascites, pericarditis and extensive venous thrombosis, due to an aggressive T cell non-Hodgkin lymphoma Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-008-0570-0Authors Elizabeth Ioannidou-Papagiannaki, Aristotle University of Thessaloniki, Hippokration General Hospital Department of Hematology, Second Department of Internal Medicine Konstantinoupoleos St 49 546 42 Thessaloniki GreeceMichael D. Diamantidis, Aristotle University of Thessaloniki, Hippokration General Hospital Department of Hematology, Second Department of Internal Medicine Konstantinoupoleos St 49 546 42 Thessaloniki GreeceIoannis Livanis, Aristotle University of Thessaloniki, Hippokration General Hospital Department of Hematology, Second Department of Internal Medicine Konstantinoupoleos St 49 546 42 Thessaloniki GreecePhilippos Klonizakis, Aristotle University of Thessaloniki, Hippokration General Hospital Department of Hematology, Second Department of Internal Medicine Konstantinoupoleos St 49 546 42 Thessaloniki GreeceStyliani Haralambidou-Vranitsa, Aristotle University of Thessaloniki, Hippokration General Hospital Department of Hematology, Second Department of Internal Medicine Konstantinoupoleos St 49 546 42 Thessaloniki GreeceEfthymia Vlachaki, Aristotle University of Thessaloniki, Hippokration General Hospital Department of Hematology, Second Department of Internal Medicine Konstantinoupoleos St 49 546 42 Thessaloniki GreeceIoannis Venizelos, Hippokration General Hospital Department of Pathology Thessaloniki GreeceIoannis Klonizakis, Aristotle University of Thessaloniki, Hippokration General Hospital Department of Hematology, Second Department of Internal Medicine Konstantinoupoleos St 49 546 42 Thessaloniki Greece Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Plasmablastic lymphoma: cytologic findings in 5 cases with unusual presentation
Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that was once believed to occur primarily in the oral cavity of human immunodeficiency virus-positive individuals. Numerous extraoral sites have also been reported to date. To the authors' knowledge, however, only 3 reports in the literature describe its cytologic features. In the current study, the cytologic findings in 5 additional patients are reported, 3 of whom had concomitant second malignancies. The goal of the current study was to define the cytomorphologic features that may help to distinguish PBL from other mimics.Five cases were identified from the pathology files for which cytology was available. The presence of the following was evaluated: cellularity, plasmablastic cells, background necrosis (BN), single-cell necrosis (SCN), lymphoglandular bodies (LGB), tingible-body macrophages (TBM), 3-dimensional clusters/sheets, and cytoplasmic vacuoles.The patients included 3 women and 2 men with an age range of 40 to 57 years. Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma. The most common cytologic features were hypercellularity (80%), plasmablastic cells (73%), SCN (73%), BN (87%), and LGB (66%). TBMs (33%) and clusters/sheets (47%) were the least common features.Although no 1 cytologic feature is diagnostic of PBL, a constellation of findings should raise suspicion. These include hypercellular specimens with abundant plasmablastic cells, LGB, SCN, and BN. However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry. As with any lymphocyte-rich aspirate, additional material should be collected for these studies. Over-reliance on adjuvant studies is discouraged because the PBL immunophenotype is not considered standard. Cancer (Cancer Cytopathol) 2008. © 2008 American Cancer Society. (Source: Cancer Cytopathology)
A multicentre phase ii clinical experience with the novel aza-epothilone ixabepilone (bms247550) in patients with relapsed or refractory indolent non-hodgkin lymphoma and mantle cell lymphoma
The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m2 weekly for three of four consecutive weeks. Patients were required to have received [le]4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 109/l and a platelet count >50 × 109/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma. (Source: British Journal of Haematology)
Impact of intensive pbsc mobilization therapy on outcomes following auto-sct for non-hodgkin's lymphoma
Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma Bone Marrow Transplantation advance online publication, August 4, 2008. doi:10.1038/bmt.2008.236 Authors: L Damon, L E Damon, K Gaensler, L Kaplan, T Martin, J Rubenstein & C Linker (Source: Bone Marrow Transplantation)
Long-term results of dose-intensive chemotherapy with g-csf support (tcc-nhl-91) for advanced intermediate-grade non-hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
| Related Articles |
Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
Oncol Res. 2008;17(3):137-49
Authors: Akutsu M, Tsunoda S, Izumi T, Tanaka M, Katano S, Inoue K, Igarashi S, Hirabayashi K, Furukawa Y, Ohmine K, Sato K, Kobayashi H, Ozawa K, Kirito K, Nagashima T, Teramukai S, Fukushima M, Kano Y
We evaluated the long-term outcome of very dose-intensive chemotherapy (TCC-NHL-91) for advanced intermediate-grade lymphoma, in which an eight-cycle regimen with 11 drugs was given with granulocyte colony-stimulating factor (G-CSF) support (total 18 weeks). Fifty-nine patients were treated during February 1, 1991 and March 31, 2001 (median age: 48 years). Forty-three patients (73%) were in a high-intermediate risk or high-risk group (HI/H) according to the age-adjusted International Prognostic Index (aa-IPI). Forty-six patients received 7 or 8 cycles of therapy. Ten of 15 patients over age 60 stopped before 7 cycles. Forty-three patients with an initial bulky mass or a residual mass received involved-field radiation. Overall, 56 patients (95%) achieved complete remission (CR). Grade 4 hematotoxicity was observed in all patients. With a median follow-up of 128 months, the 10-year overall survival (OS) and progression-free survival (PFS) rates were 76% and 61%, respectively. Neither aa-IPI risk factors nor the index itself was associated with response, OS, or PFS. One patient died of sepsis during the therapy and one died of secondary leukemia. This retrospective study suggests that the TCC-NHL-91 regimen achieves high CR, OS, and PFS in patients with advanced intermediate-grade lymphoma up to 60 years old and may be a valuable asset in the management of this disease. Further evaluation and prospective studies of the TCC-NHL-91 are warranted.
PMID: 18669165 [PubMed - in process]
(Source: Oncology Research)Tricyclic-antidepressants linked to non-hodgkin's lymphoma.
Page: 19 (Source: Inpharma Weekly)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Tricyclic-antidepressants linked to non-hodgkin's lymphoma.
Page: 1 (Source: Reactions Weekly)
The clinical application of fibroblast interferon—an overview
Abstract Preclinical as well as clinical studies with fibroblast interferon (IFN) are still lagging behind on those with leukocyte interferon. Its side-effects seem to be less pronounced than those of human IFN-α, yet it may be slightly pyrogenic after intravenous injection. Pyrogenicity of current impure preparations might for the larger part be due to impurities. Higher doses of HuIFN-β than of HuIFN-α are required to obtain measurable blood titers by intramuscular injections. Since there is concern about this being due to destruction of the interferon before it has reached its target organ(s), most current clinical studies use either local (e.g. intratumoral) treatment or intravenous infusions. A study of topical treatment for acute rhinovirus infection has indicated that there is very little if any chance for fibroblast interferon to be a clinically useful substance to prevent or cure common cold. In herpetic dendritic keratitis eye drops of fibroblast interferon may be useful as such or in combination with debridement. Topical treatment of warts (multiple intralesional injections) has been shown to yield a high success rate, especially in the case of verrucae vulgares, but less so in the case of verrucae planae juveniles. Studies on condyloma accuminatum are not so far advanced as to permit a documented conclusion. Topical (intralesional) treatment of neoplastic diseases has been investigated, especially in Japan, to demonstrate that fibroblast interferon does have an antineoplastic effectin vivo. While there seems to be little doubt that local delivery does indeed cause tumor nodules to regress, the question is whether this procedure can offer a true clinical benefit to the patient. Systemic (intravenous) administration for chronic hepatitis B has been investigated further: given alone or in combination with adenine-arabinoside, fibroblast interferon seems to be able to reduce the level of viral activity. Whether this will lead to a generally accepted treatment of chronic active hepatitis is difficult to say at this moment. In treating herpes zoster in cancer patients, results have been obtained which are comparable to those found for leukocyte interferon. The practical significance of this finding must be seen in the perspective of recent developments in the chemotherapy of herpes zoster. In breast cancer patients given intramuscular injections, metastases in the skin, but not in other organs, showed alterations suggestive of an effect on tumor progression. Yet there was no true clinical benefit for the patient. In other tumors, e.g. head and neck epithelioma, no effect was seen. Intravenous infusions have met with some success in nasopharyngeal carcinoma: temporary stabilization or regression occurred, but no definitive cures were noted. A large neuroblastoma trial yielded negative results. Disappointing results were also obtained in non-Hodgkin's lymphoma. In initial studies on myeloma and brain tumors ‘response rates’ of 25% were recorded; the significance of this in terms of clinical benefit to the patient is not clear yet. Content Type Journal ArticleDOI 10.1007/BF02934979Authors A. Billiau, University of Leuven Rega Institute Minderbroedersstraat 10 B-3000 Leuven Belgium Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 Journal Volume Volume 1 Journal Issue Volume 1, Number 2 / June, 1984 (Source: Medical Oncology)
Human immunodeficiency virus-related non-hodgkin's lymphoma.
| Related Articles |
Human immunodeficiency virus-related non-Hodgkin's lymphoma.
Haematologica. 2008 Aug;93(8):1129-32
Authors: Ribera JM, Navarro JT
PMID: 18669976 [PubMed - in process]
(Source: Haematologica)A unique case of mantle cell lymphoma with an aberrant cd5-/cd10+ immunophenotype and typical morphology.
A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+ immunophenotype and typical morphology.
Arch Pathol Lab Med. 2008 Aug;132(8):1346-9
Authors: Sriganeshan V, Blom TR, Weissmann DJ
Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma with a poor prognosis that may be confused with less aggressive diseases, such as small lymphocytic lymphoma and follicular lymphoma. In many cases immunophenotyping, particularly analysis of reactivity for CD5 and CD10, is an important adjunct to morphology that usually distinguishes MCL from follicular lymphoma; the former is CD5(+)/CD10(-), whereas follicular lymphoma is the reverse. We report a case of MCL, initially diagnosed as follicular lymphoma, that at presentation expressed neither CD5 nor CD10. At relapse, it was still CD5(-), but CD10 was now detected. Studies for a t(11;14) translocation and CYCLIN D1 protein expression, however, permitted a revised diagnosis of MCL. An MCL with this immunophenotype and classical morphology has not been previously reported.
PMID: 18684040 [PubMed - in process]
(Source: Archives of Pathology and Laboratory Medicine)Follicular lymphoma in a x-linked lymphoproliferative syndrome carrier female.
Follicular lymphoma in a X-linked lymphoproliferative syndrome carrier female.
Scand J Immunol. 2008 Aug;68(2):153-8
Authors: Woon ST, Ameratunga R, Croxson M, Taylor G, Neas K, Edkins E, Browett P, Gane E, Munn S
X-linked lymphoproliferative (XLP) syndrome is a rare primary immune-deficiency disorder caused by mutations of the SH2D1A or XIAP genes. Males with the disorder are usually in good health until contracting Epstein-Barr virus (EBV) whereupon the majority of patients die from fulminant infectious mononucleosis, lymphoma or hypogammaglobulinaemia. This report describes a female carrier with an XLP phenotype who was retrospectively identified after her grandson died from the disorder. Subsequent genetic testing identified the patient's mother and affected maternal grandmother as XLP carriers. The family's medical records were significant. The proband had lymphoma at ages 2 and 8 and made a full recovery following treatment. Both the maternal grandmother and uncle died of non-Hodgkin's lymphoma. We were concerned that the XLP carrier mother may be predisposed to lymphoma if the normal X chromosome is skewed towards inactivation. The human androgen receptor assay detected random X chromosome inactivation in the carrier mother. EBV was not detected in the lymphoma tissues of the proband and his grandmother, confirming previous findings that EBV is not always associated with lymphoma in XLP. More significantly, our study highlights the importance of identifying XLP in families with a high incidence of lymphoma.
PMID: 18702745 [PubMed - in process]
(Source: Scandinavian Journal of Immunology)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-hodgkin's lymphoma.
Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Int J Lab Hematol. 2008 Aug;30(4):292-9
Authors: Hashino S, Morioka M, Irie T, Shiroshita N, Kawamura T, Suzuki S, Iwasaki H, Umehara S, Kakinoki Y, Kurosawa M, Kahata K, Izumiyama K, Kobayashi H, Onozawa M, Takahata M, Fujisawa F, Kondo T, Asaka M
High costs of molecule-targeted drugs, such as rituximab, ibritumomab, and tositumomab have given rise to an economical issue for treating patients with non-Hodgkin's lymphoma (NHL). Granulocyte colony-stimulating factors (G-CSFs), which are also expensive, are widely used for treating neutropenia after chemotherapy. In Japan, lenograstim at 2 mug/kg (about 100 mug/body) or filgrastim at 50 mug/m(2) (about 75 mug/body) is commonly administered for patients with NHL after chemotherapy. Therefore, cost-effectiveness is an important issue in treatment for NHL. Patients with advanced-stage NHL who needed chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen with or without rituximab were enrolled in this randomized cross-over trial to investigate the efficacy and safety of low-dose G-CSF. Half of the patients were administered 75 mug filgrastim in the first course after neutropenia and 50 mug lenograstim in the second course, and the other half were crossed over. Forty-seven patients were enrolled in this cross-over trial, and 24 patients completed the trial. Frequencies and durations of grade 4 leukocytopenia and neutropenia were similar in the two groups. Severe infection was rare and was observed at similar frequency. Frequencies of antibiotics use were also similar. The total cost of G-CSF (cost/drug x duration of administration) was significantly lower in patients who received 50 mug lenograstim. Hence, a low dose of lenograstim might be safe, effective and pharmaco-economically beneficial in patients with advanced-stage NHL.
PMID: 18665826 [PubMed - in process]
(Source: International Journal of Laboratory Hematology)Unexpected benefit of allergies
Long-suffering victims of allergies such as asthma and hay fever might enjoy a surprise benefit, according to research led by the University of New South Wales (UNSW). In a paper presented at an international symposium in Sydney, the researchers show that people with one of these atopic diseases are up to 25 percent less likely to get the most common type of Non-Hodgkin Lymphoma (NHL). (Source: Asthma / Respiratory News From Medical News Today)
Lenalidomide offers effective treatment for patients with relapsed or refractory aggressive non-hodgkin's lymphoma
(Source: Inpharma)
Phase ii study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a wisconsin oncology network study
Arsenic trioxide (As2O3) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies. Cell death from As2O3 may be the result of oxidative stress. Agents which deplete intracellular glutathione, such as ascorbic acid (AA), may potentiate arsenic-mediated apoptosis. This multi-institution phase II study investigated a novel dosing schedule of As2O3 and AA in patients with relapsed or refractory lymphoid malignancies. Patients received As2O3 0.25 mg/kg IV and AA 1000 mg IV for five consecutive days during the first week of each cycle followed by twice weekly infusions during weeks 2-6. Cycles were repeated every 8 weeks. The primary end point was objective response. In a subset of patients, sequential levels of intracellular glutathione and measures of Bcl-2 and Bax gene expression were evaluated in peripheral blood mononuclear cells during treatment. Seventeen patients were enrolled between March 2002 and February 2004. The median age was 71, and the majority of enrolled patients had non-Hodgkin's lymphoma (12/17). Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%. The trial, which had been designed as a two-stage study, was closed after the first stage analysis due to lack of activity. Haematologic toxicities were the most commonly reported events in this heavily pre-treated population, and comprised the majority of grade 3 and 4 toxicities. Intracellular depletion of glutathione was not consistently observed during treatment. As2O3 and AA in this novel dosing strategy was generally well tolerated but had limited activity in patients with relapsed and refractory lymphoid malignancies. Copyright © 2008 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Agricultural pesticides and risk of childhood cancers.
| Related Articles |
Agricultural pesticides and risk of childhood cancers.
Int J Hyg Environ Health. 2008 Jul 31;
Authors: Carozza SE, Li B, Wang Q, Horel S, Cooper S
Agricultural pesticide applications have the potential for significant drift beyond the target spray area and may result in exposure to non-farming residents in surrounding communities. Using geographic information system (GIS) methods, 1778 childhood cancer cases and 1802 controls born in Texas between 1990 and 1998 were assigned probable agricultural pesticide exposure based on proximity of birth residence to crop fields. Multivariate modeling was used to estimate odds ratios and 95% confidence intervals for selected cancers. For most childhood cancers, we found no evidence of elevated risk associated with residential proximity at birth to cropland. There was an overall pattern of increased risk for germ-cell tumors but the odds ratios were based on few number of exposed cases. There was also some indication of increased risk for non-Hodgkin lymphoma (NHL) and Burkitt lymphoma, but point estimates were imprecise and not statistically significant. Previous studies have assessed pesticide exposure primarily based on parental occupational history or household use, while our focus was on agricultural pesticides and so may represent a different array of chemical agents occurring at lower doses.
PMID: 18675586 [PubMed - as supplied by publisher]
(Source: International Journal of Hygiene and Environmental health)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Early study finds increased non-hodgkin's lymphoma in long-term users of tricyclic antidepressants
A population-based observational study from Denmark found an increased risk for non-Hodgkin's lymphoma among users of tricyclic antidepressants. Medscape Medical News (Source: Medscape Medical News Headlines)
Lenalidomide offers effective treatment for patients with relapsed or refractory aggressive non-hodgkin's lymphoma.
Page: 17 (Source: Inpharma Weekly)
Neutrophil role in in vivo anti-lymphoma activity of rituximab: fcgr3b-na1/na2 polymorphism does not influence response and survival after rituximab treatment
Background: Neutrophils could play an important role in in vivo rituximab anti-lymphoma activity. FcRIIIb is expressed only by neutrophils and FcRIIIb-neutrophil antigen (NA)1/NA2 polymorphism influenced phagocytosis of immunoglobulin G1-opsonized particles. We formulated the hypothesis that if neutrophils are critical cells for in vivo rituximab activity, FcRIIIb-NA1/NA2 polymorphism could influence the response to rituximab. Patients and methods: FCGR3B-NA1/NA2 genotypes were determined in 46 patients having received rituximab for a previously untreated, follicular, non-Hodgkin's lymphoma. The clinical response and the disappearance of the BCL2-JH gene rearrangement in both peripheral blood and bone marrow were evaluated at 2 months (M2) and each year during 7 years. Results: They were 13% homozygous for FCGR3B-NA1, 61% homozygous for FCGR3B-NA1/NA2 and 26% heterozygous. The objective response rates at M2 were 67% in homozygous FCGR3B-NA1 patients compared with 75% in homozygous FCGR3B-NA2 and 75% in heterozygous patients (not significant). We found no difference for progression-free and overall survival by FCGR3B-NA1/NA2 genotypes. Conclusion: These results indicate no association between FCGR3B-NA1/NA2 polymorphism and response to rituximab indicating no significant role of phagocytosis mediated by neutrophils in in vivo mechanism of rituximab activity. (Source: Annals of Oncology)
Solid variant of primary effusion lymphoma in successfully treated hiv infection: a case report
Primary effusion lymphoma (PEL) is a unique form of non-Hodgkin lymphoma, mainly met in severely immunocompromised, HIV-positive patients. PEL is aetiologically related to human herpes virus-8 (HHV-8) and it usually presents as a lymphomatous body cavity effusion in the absence of a solid tumour mass. Recently, cases of HIV-positive patients with HHV-8-positive solid tissue lymphomas, not associated with an effusion, have been reported (solid variant of PEL). The prognosis of PEL is reported to be poor. We report a case of an HIV-positive patient with a typical solid variant of PEL without effusion. Interestingly, his disease developed while being on stable antiretroviral therapy (ART) with high CD4 counts. He had a relatively long survival with chemotherapy and ART. (Source: International Journal of STD and AIDS)
Severe right ventricular inflow obstruction by non-hodgkin lymphoma
(Source: British Journal of Haematology)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-hodgkin's lymphoma.
| Related Articles |
Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
Neoplasma. 2008;55(2):107-12
Authors: Vranovsky A, Ladicka M, Lakota J
A single center, retrospective analysis evaluating the outcome of patients with poor-risk aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT) as a part of firstline therapy. Forty-seven patients younger than 65 years with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL) or alk-negative anaplastic large cell lymphoma (ALCL) underwent ASCT between July 1997 and November 2005. Patients with DLBCL and alk-negative ALCL had 2 or 3 age-adjusted International Prognostic Index risk factors. All patients were transplanted after MACOP-B induction therapy followed by 2 courses of DHAP and myeloablative chemotherapy BEM or CBV. The complete response rate to the high-dose therapy was 79% with an estimated 5-year progression-free survival of 66%. At a median follow-up of 35 months (range, 16 to 112 months) the estimated overall survival at five years was 59%. There were 4 treatment-related deaths. Twenty-nine of 47 patients remain in complete remission. Our results confirm the efficacy of high-dose therapy with ASCT during first-line treatment of patients with poor-prognosis aggressive lymphoma, with substantial number of patients cured by using this treatment approach.
PMID: 18652043 [PubMed - in process]
(Source: Neoplasma)Spontaneous bacterial peritonitis from salmonella : an unusual bacterium with unusual presentation
Abstract Spontaneous bacterial peritonitis (SBP) is a common cause of morbidity and mortality in patients with advanced cirrhosis and portal hypertension. While gram-negative rods and Enterococcus species are the common offending organisms, Salmonella has also been recognized as a rare and atypical offending organism. Atypical features of Salmonella SBP include both its occurrence in cirrhotic patients with immunosuppressive state and its lack of typical neutroascitic response. Diagnosis is often delayed as it requires confirmation from ascitic fluid culture. We report a case of Salmonella SBP occurring in a patient with decompensated cryptogenic cirrhosis with concurrent low-grade non-Hodgkin lymphoma and prior treatment with rituximab. Physicians should be aware of the atypical presentation, especially in cirrhotic patients who are immunosuppressed. Content Type Journal ArticleCategory Case ReportDOI 10.1007/s12072-008-9087-9Authors Harshal Rajekar, Asian Center for Liver Diseases and Transplantation Gleneagles Hospital Annexe Block #02-37, 6A Napier Road Singapore Singapore 258500Chun-Tao Wai, Asian Center for Liver Diseases and Transplantation Gleneagles Hospital Annexe Block #02-37, 6A Napier Road Singapore Singapore 258500Kang-Hoe Lee, Asian Center for Liver Diseases and Transplantation Gleneagles Hospital Annexe Block #02-37, 6A Napier Road Singapore Singapore 258500Sin-Yew Wong, Asian Center for Liver Diseases and Transplantation Gleneagles Hospital Annexe Block #02-37, 6A Napier Road Singapore Singapore 258500Kai-Chah Tan, Asian Center for Liver Diseases and Transplantation Gleneagles Hospital Annexe Block #02-37, 6A Napier Road Singapore Singapore 258500 Journal Hepatology InternationalOnline ISSN 1936-0541Print ISSN 1936-0533 (Source: Hepatology International)
Scholastic achievement of children with lymphoma or wilms tumor at the end of comprehensive education - a nationwide, register-based study
Cancer treatment may affect school performance. School report grades after childhood lymphomas and Wilms tumor have not been previously reported. All Finnish patients with Wilms tumor (N = 74), Hodgkin lymphoma (HL) (N = 99) and non-Hodgkin lymphoma (NHL) (N = 94) who were born in 1974-1986 and had achieved the age of 16 years were identified from the Finnish cancer registry. Population controls (N = 1329) were matched for age, gender and residence. Their 9th grade school reports were obtained from Statistics Finland. The overall average and grades for mother tongue, first foreign language, mathematics and physical education were compared between the patients and their controls. Almost all the patients (>98%) had finished their comprehensive school. NHL patients had lower overall averages than their controls (difference -0.27 grade units; 95% CI -0.39, -0.15). Irradiation or age at diagnosis did not explain this difference in NHL patients. The grades of NHL patients were significantly lower than those of their controls in each academic school subject, especially in mathematics (-0.45; 95% CI -0.63, -0.27). In mother tongue, girls with irradiation had greatest difference (-0.66, 95% CI -0.99, -0.34) to their controls. Patients with HL and Wilms tumor performed similarly or even better than their controls in all academic subjects. Grades for physical education were impaired in Wilms tumor patients (-0.20; 95% CI -0.33, -0.06). Impairment of school report grades was observed in patients with NHL. The difference to controls was greatest in mathematics. The patients with HL and Wilms tumor, who had not received any central nervous system directed therapy, achieved equally good grades as their controls in all the academic subjects. © 2008 Wiley-Liss, Inc. (Source: International Journal of Cancer)
Primary extranodal non-hodgkin lymphoma of the oral cavity.
Page: 1183DOI: 10.1097/SCS.0b013e3181764b56Authors: Boulaadas, Malik MD *; Benazzou, Salma MD *; Sefiani, Sanae MD +; Nazih, Nawal MD ++; Essakalli, Leila MD ++; Kzadri, Mohamed MD *++ (Source: Journal of Craniofacial Surgery)
Social inequality and incidence of and survival from hodgkin lymphoma, non-hodgkin lymphoma and leukaemia in a population-based study in denmark, 1994-2003.
| Related Articles |
Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994-2003.
Eur J Cancer. 2008 Jul 24;
Authors: Roswall N, Olsen A, Christensen J, Rugbjerg K, Mellemkjær L
We investigated the effects of socioeconomic, demographic and health-related indicators on the incidence of and survival from haematological cancers diagnosed in 1994-2003 with follow-up through 2006 in Denmark using information from nationwide registers. The analyses were based on data on 636 patients with Hodgkin lymphoma (HL), 4516 with non-Hodgkin lymphoma (NHL) and 3486 with leukaemia in a cohort of 3.22 million people born between 1925 and 1973 and aged >/=30 years. No consistent differences in incidence were seen by socioeconomic position, but an association with comorbidity was found. Patients in the lowest socioeconomic groups and those with other serious illnesses, especially men, had a worse survival of NHL. Survival results for leukaemia tended to be similar to those for NHL, although associations were generally weaker and insignificant. Thus, there were no strong associations between socioeconomic position and the incidence of these cancers; survival after NHL might be affected.
PMID: 18657412 [PubMed - as supplied by publisher]
(Source: European Journal of Cancer)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
| Related Articles |
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
Biol Blood Marrow Transplant. 2008 Aug;14(8):904-12
Authors: Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P
We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes for patients with either Hodgkin lymphoma (HL, n = 21) or non-Hodgkin lymphoma (NHL, n = 19) receiving HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were analyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58%) patients had a Karnofsky performance score <90. HCT2 was performed >1 year after HCT1 in 82%. The probability of treatment-related mortality at day 100 was 11% (95% confidence interval [CI], 3%-22%). The 1-, 3-, and 5-year probabilities of PFS were 50% (95% CI, 34%-66%), 36% (95% CI, 21%-52%), and 30% (95% CI, 16%-46%), respectively. Corresponding probabilities of survival were 65% (95% CI, 50%-79%), 36% (95% CI, 22%-52%), and 30% (95% CI, 17%-46%), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients (73%) have died, 18 (62%) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options.
PMID: 18640574 [PubMed - in process]
(Source: Biology of Blood and Marrow Transplantation)Rituximab blocks binding of radiolabeled anti-cd20 antibodies (ab) but not radiolabeled anti-cd45 ab
Rituximab therapy is associated with a long in vivo persistence, yet little is known about the effect of circulating rituximab on B-cell non-Hodgkin lymphoma (B-NHL) targeting by the other available anti-CD20 monoclonal antibodies (MoAbs) 131iodine-tositumomab and 90yttrium-ibritumomab tiuxetan. Therefore we assessed the impact of preexisting rituximab on the binding and efficacy of second anti-CD20 MoAbs to B-NHL and determined whether targeting an alternative lymphoma-associated antigen, CD45, could circumvent this effect. We demonstrated that rituximab concentrations as low as 5 µg/mL nearly completely blocked the binding of a second anti-CD20 MoAbs (P < .001), but had no impact on CD45 targeting (P = .89). Serum from patients with distant exposures to rituximab also blocked binding of anti-CD20 MoAbs to patient-derived rituximab-naive B-NHL at concentrations at low as 7 µg/mL, but did not affect CD45 ligation. A mouse xenograft model (Granta, FL-18, Ramos cell lines) showed that rituximab pretreatment significantly reduced B-NHL targeting and tumor control by CD20-directed radioimmunotherapy (RIT), but had no impact on targeting CD45. These findings suggest that circulating rituximab impairs the clinical efficacy of CD20-directed RIT, imply that novel anti-CD20 MoAbs could also face this same limitation, and indicate that CD45 may represent an alternative target for RIT in B-NHL. (Source: Blood)
A prospective study of 728 cases of non-hodgkin lymphoma from a single laboratory in shanghai, china.
A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China.
Int J Hematol. 2008 Jul 23;
Authors: Gross SA, Zhu X, Bao L, Ryder J, Le A, Chen Y, Wang XQ, Irons RD
The frequency of subtypes of lymphoid neoplasms was determined in a prospective series of 831 patients presenting at 29 Shanghai hospitals over a 4-year period. Diagnosis and classification was established in a single laboratory according to the 2001 WHO classification system. The frequency of non-Hodgkin lymphoma was 87.6% (n = 728) and Hodgkin lymphoma was 12.4% (n = 103). The most prevalent NHL subtypes diagnosed using WHO criteria were diffuse large B cell lymphoma (DLBCL), precursor B lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Although a low incidence has been reported in some Asian populations, CLL/SLL was commonly encountered, indicating that chronic lymphoid neoplasms are not rare in Shanghai. Consistent with previous reports, our findings indicate a decrease in the frequency of follicular lymphoma and an increase in T cell neoplasms compared to the West. Precursor T lymphoblastic leukemia/lymphoma, anaplastic large T cell lymphoma, aggressive NK cell leukemia, angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma were prominent subtypes of T cell NHL.
PMID: 18648906 [PubMed - as supplied by publisher]
(Source: International Journal of Hematology)Good and evil: a cancer vaccine from tobacco plants [news]
In the first human trial of its kind, a vaccine grown in genetically engineered tobacco plants has proved to be safe, paving the way to one day use it to help combat a potentially fatal form of non-Hodgkin's lymphoma. [More] (Source: Scientific American - Official RSS Feed)
Powered by FirstRSS Plugin
